According to filings with the U.S. Securities and Exchange Commission, Volastra Therapeutics is raising up to $30,099,998.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Volastra Therapeutics
Volastra Therapeutics is a clinical-stage biotechnology company based in New York City, dedicated to discovering and developing oncology therapeutics. The company focuses on exploiting chromosomal instability (CIN), a key vulnerability in various cancers, to create novel approaches for treatment. Founded by Drs. Lewis Cantley, Olivier Elemento, and Samuel Bakhoum, Volastra is advancing a pipeline of synthetic lethal and immune-activating therapies. Their lead programs include two distinct KIF18A inhibitors, VLS-1488 and sovilnesib, both of which are in Phase 1 clinical trials for advanced cancers, including platinum-resistant high-grade serous ovarian cancer, with VLS-1488 having received FDA Fast Track designation. Volastra also engages in strategic partnerships, including collaborations with Microsoft for AI-driven biomarker identification and Bristol Myers Squibb for drug discovery, to further its mission of improving outcomes for patients with metastatic cancers.

To learn more about Volastra Therapeutics, visit https://www.volastratx.com/
Volastra Therapeutics Linkedin Page: https://www.linkedin.com/company/volastra-therapeutics/

Contact:
David Southwell, Chief Executive Officer
646-344-1248

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.